X4 Pharmaceuticals Inc
XFOR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$332.14M
Close$
$2.71
19.1% downside
Current Fair Value
19.1% downsideOvervalued by 19.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $332.14 Million |
|---|---|
| Enterprise Value | $138.35 Million |
| Earnings per Share | $-1.87 |
| Beta | 0.35 |
| Outstanding Shares | 126,344,020 |
Return
| Return on Equity | -57.98% |
|---|---|
| Return on Assets | -35.62% |
| Return on Invested Capital | -42.95% |
Valuation & Multiples
| P/E Ratio | -2.79 |
|---|---|
| PEG | 7.5 |
| Price to Sales | - |
| Price to Book Ratio | 3.35 |
| Enterprise Value to Revenue | 8.73 |
| Enterprise Value to EBIT | -1.38 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS Estimate
$-0.19
Consensus analyst estimateRevenue Estimate
$2.26 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.18
Consensus analyst estimateRevenue Estimate
$2.30 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 76.11% |
|---|---|
| Total Invested | $63,371▼ 99.99% |
| Investors Holding | 3▼ 88.00% |
About X4 Pharmaceuticals Inc
72 employees
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare di...